Parallel Advisors, LLC Spectrum Pharmaceuticals Inc Transaction History

Parallel Advisors, LLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 20, 2024	BUY	$0.38 - $1.07 $5,320 - $14,980	14,000 New	14,000 $10,000
Q3 2022 Nov 10, 2022	BUY	$0.43 - $1.56 $1,720 - $6,240	4,000 Added 40.0%	14,000 $6,000
Q2 2022 Aug 01, 2022	SELL	$0.7 - $1.4 $468 - $937	-670 Reduced 6.28%	10,000 $8,000
Q1 2022 Apr 28, 2022	BUY	$0.63 - $1.59 $3,572 - $9,015	5,670 Added 113.4%	10,670 $13,000
Q4 2021 Jan 20, 2022	SELL	$1.27 - $2.42 $829 - $1,580	-653 Reduced 11.55%	5,000 $6,000
Q3 2021 Nov 02, 2021	BUY	$2.15 - $3.82 $672 - $1,195	313 Added 5.86%	5,653 $12,000
Q2 2021 Aug 06, 2021	BUY	$2.89 - $4.45 $982 - $1,513	340 Added 6.8%	5,340 $20,000
Q4 2020 Feb 02, 2021	BUY	$3.38 - $5.14 $16,693 - $25,386	4,939 Added 8096.72%	5,000 $17,000
Q3 2020 Oct 27, 2020	BUY	$2.99 - $4.9 $182 - $298	61 New	61 $0
Q4 2019 Jan 30, 2020	SELL	$3.5 - $10.35 $7,875 - $23,287	-2,250 Closed	0 $0
Q3 2019 Nov 01, 2019	SELL	$7.03 - $9.7 $843 - $1,164	-120 Reduced 5.06%	2,250 $19,000
Q3 2017 Nov 15, 2017	BUY	$8.75 - $14.07 $20,737 - $33,345	2,370 New	2,370 $44,000
Q3 2017 Nov 14, 2017	SELL	$8.75 - $14.07 $20,895 - $33,599	-2,388 Closed	0 $0
Q2 2017 Aug 07, 2017	BUY	N/A	2,388	2,388 $18,000

115K

Ticker SPPI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,164,000
Description
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor ...

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Parallel Advisors, LLC with notifications on news.